173 related articles for article (PubMed ID: 2984249)
21. Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine against different herpes simplex virus strains in cell culture and against experimental herpes encephalitis in mice.
Reefschläger J; Wutzler P; Thiel KD; Bärwolff D; Langen P; Sprössig M; Rosenthal HA
Antiviral Res; 1982 Oct; 2(5):255-65. PubMed ID: 6295273
[TBL] [Abstract][Full Text] [Related]
22. Selection of HSV-1 TK gene-transfected murine mammary carcinoma cells resistant to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and ganciclovir (GCV).
Degrève B; De Clercq E; Balzarini J
Gene Ther; 2000 Sep; 7(18):1543-52. PubMed ID: 11021592
[TBL] [Abstract][Full Text] [Related]
23. Different in vitro effects of dual combinations of anti-herpes simplex virus compounds.
Schinazi RF; Nahmias AJ
Am J Med; 1982 Jul; 73(1A):40-8. PubMed ID: 6285731
[TBL] [Abstract][Full Text] [Related]
24. Comparison of four methods for typing low-passage herpes simplex virus isolates.
Mayo D; Hilliard J; Landry M; Egbertson S; Mirkovic R
Intervirology; 1985; 23(2):112-5. PubMed ID: 2984142
[TBL] [Abstract][Full Text] [Related]
25. The antiviral spectrum of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
De Clercq E
J Antimicrob Chemother; 1984 Aug; 14 Suppl A():85-95. PubMed ID: 6092320
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
De Clercq E; Desgranges C; Herdewijn P; Sim IS; Jones AS; McLean MJ; Walker RT
J Med Chem; 1986 Feb; 29(2):213-7. PubMed ID: 3005566
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of three methods for typing herpes simplex virus.
Salmerón F; Pérez Breña P; Rojas JM; Hernáez Lobo R; Tabarés E
Eur J Clin Microbiol; 1987 Dec; 6(6):664-7. PubMed ID: 2831045
[TBL] [Abstract][Full Text] [Related]
28. Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
Balzarini J; de Clercq E; Ayusawa D; Seno T
FEBS Lett; 1985 Jun; 185(1):95-100. PubMed ID: 2987041
[TBL] [Abstract][Full Text] [Related]
29. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).
De Clercq E
Med Res Rev; 2005 Jan; 25(1):1-20. PubMed ID: 15389733
[TBL] [Abstract][Full Text] [Related]
30. Altered thymidine-thymidylate kinases from strains of herpes simplex virus with modified drug sensitivities to acyclovir and (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Fyfe JA; McKee SA; Keller PM
Mol Pharmacol; 1983 Sep; 24(2):316-23. PubMed ID: 6310366
[TBL] [Abstract][Full Text] [Related]
31. Expression of herpes simplex virus type 1 recombinant thymidine kinase and its application to a rapid antiviral sensitivity assay.
Shiota T; Lixin W; Takayama-Ito M; Iizuka I; Ogata M; Tsuji M; Nishimura H; Taniguchi S; Morikawa S; Kurane I; Mizuguchi M; Saijo M
Antiviral Res; 2011 Aug; 91(2):142-9. PubMed ID: 21669227
[TBL] [Abstract][Full Text] [Related]
32. Intentional reactivation of latent ocular herpes infection during BVDU therapy.
Trousdale MD; Robin JB; Willey DE; De Clercq E
Curr Eye Res; 1987 Dec; 6(12):1471-7. PubMed ID: 2827960
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Harris SA; McGuigan C; Andrei G; Snoeck R; De Clercq E; Balzarini J
Antivir Chem Chemother; 2001 Sep; 12(5):293-300. PubMed ID: 11900348
[TBL] [Abstract][Full Text] [Related]
34. Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes.
Schubert A; Gentner E; Bohn K; Schwarz M; Mertens T; Sauerbrei A
Antiviral Res; 2014 Jul; 107():16-22. PubMed ID: 24747042
[TBL] [Abstract][Full Text] [Related]
35. Isolation of bromovinyldeoxyuridine-resistant strains of herpes simplex virus and successful chemotherapy of mice infected with one such strain by using acyclovir.
Field HJ; Neden J
Antiviral Res; 1982 Oct; 2(5):243-54. PubMed ID: 6295272
[TBL] [Abstract][Full Text] [Related]
36. Induction of nuclear deoxyribopyrimidine triphosphatase and sensitivity of clinical isolates of herpes simplex virus to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Wohlrab F; Mayo DR; Hsiung GD; Francke B
Antiviral Res; 1983 Mar; 3(1):1-5. PubMed ID: 6135391
[TBL] [Abstract][Full Text] [Related]
37. Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir.
Reefschläger J; Wutzler P; Thiel KD; Herrmann G
Antiviral Res; 1986 Mar; 6(2):83-93. PubMed ID: 3010858
[TBL] [Abstract][Full Text] [Related]
38. The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs.
Field H; McMillan A; Darby G
J Infect Dis; 1981 Feb; 143(2):281-5. PubMed ID: 6260876
[TBL] [Abstract][Full Text] [Related]
39. Cytopathogenicity, drug susceptibility, and thymidine kinase activity of a retinovirulent herpes simplex virus type 2.
Langford MP; Colacino JM; Kaiwar R; Mahjoub SB; Ganley JP
J Med Virol; 1990 Aug; 31(4):301-5. PubMed ID: 2176674
[TBL] [Abstract][Full Text] [Related]
40. The effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on DNA repair and mutagenesis of herpes simplex virus type 1.
Bubley GJ; Balzarini J; Crumpacker CS; de Clercq E; Schnipper LE
Virology; 1987 Nov; 161(1):242-4. PubMed ID: 2823464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
